ML224 (NCGC00242364; ANTAG3) is a thyroid-stimulating hormone receptor TSHR counter-agonist with an IC50 of 2.1uM.
TAS4464 is a highly selective inhibitor of NEDD8 activated enzyme (NAE),IC50 The value is 0.955 nM.
Avermectin B1 (Abamectin) is an orally anti-infection agent, which can be used in the research of parasitic worms, insect pests, agriculture and animal husbandry. Avermectin B1 can also induce the production of ROS and induces cytotoxicity, apoptosis and autophagy.
TAS4464 is a highly selective inhibitor of NEDD8 activated enzyme (NAE),IC50 The value is 0.955 nM.
TAS4464 is a highly selective inhibitor of NEDD8 activated enzyme (NAE),IC50 The value is 0.955 nM.
Ly-3475070 is the first oral bioavailable, selective and extracellular enzyme CD73 (cluster of Differentiation 73, 5'-ecto-nucleotidase, 5' -nt, Ecto -5'-nucleotidase) inhibitor.
Giredestrant (GDC-9545, RG6171) is an orally active, selective estrogen receptor degrader (SERD) with best-in-class potential to compete with estradiol in the ER ligand binding domain and induce conformational changes.Giredestrant has antitumor activity.
Neriifolin, a cardiac glycoside that penetrates the central nervous system, is a typeNa, K-ATPase++ of inhibitors. Neriifolin targets beclin 1, inhibits the formation of LC3-associated phagosomes, and improves the development of experimental autoimmune encephalomyelitis (EAE).
SRS16-86 is a potent inhibitor of ferroptosis. SRS16-86 is more metabolically and plasma-stable in vivo than Ferrostatin-1. SRS16-86 can be used for renal ischemia-reperfusion injury (IRI) and spinal cord injury (SCI) studies.
GSK3145095 is a potent inhibitor of the oral activity RIP1 kinase with an IC50 of 6.3 nM with potential antitumor and immunomodulatory activity.
GSK3145095 is a potent inhibitor of the oral activity RIP1 kinase with an IC50 of 6.3 nM with potential antitumor and immunomodulatory activity.
Etelcalcetide Hydrochloride (AMG 416 Hydrochloride) is a synthetic peptide that acts as a calcium-sensitive receptor (CaSR) activator. Etelcalcetide hydrochloride effectively reduces parathyroid hormone (PTH) concentration in patients with secondary hyperparathyroidism undergoing hemodialysis.